Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Large Simple Trials Need FDA Boost, IoM Report Says

Executive Summary

“Clear specific guidance” from the agency would help close the perception gap between what types of data industry thinks FDA wants and what the agency actually expects, according to a summary of a 2012 Institute of Medicine workshop.

Advertisement

Related Content

FDA’s Temple Pushes Feasibility, Cost-Savings Of Large, Simple Trials
FDA’s Clinical Trial Inclusion Policy Sold As Mild And Gentle
Merck’s Vorapaxar CV Outcome Follow-Up Success Not Ready To Become Standard
FDA’s Clinical Trial Inclusion Policy Sold As Mild And Gentle
FDA Policy In Biosimilars, “Breakthrough” And Social Media Under New Management
FDA’s Guide For Selectively Collecting Safety Data
Targeted Safety Data Collection Needs International Agreement, Industry Tells FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS055670

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel